原发性肝癌分子生物学机制和相关分子靶向药物的研究进展  

Molecular pathogenesis and molecular targeted agents for primary liver cancer

作　　者：陈业盛 孙志为[1] 孟春城[1] 唐建中[1] 李星逾[1] 王峻峰[1] 刘林[1] 张丽菊[1] 

机构地区：[1]云南省第一人民医院肝胆一科,云南省昆明市650032

出　　处：《世界华人消化杂志》2015年第6期914-924,共11页World Chinese Journal of Digestology

基　　金：云南省卫生科技基金资助项目;No.2012WS0076;云南省肿瘤转化医学工程技术研究中心基金资助项目;No.2011DH013~~

摘　　要：目前,我国原发性肝癌(primary liver cancer,P L C)的治疗形势十分严峻,其从根本上取决于对PLC发病机制的系统认识.近年来,随着相关分子机制,诸如信号转导通路的不断阐明,PLC的治疗正面临新的机遇和挑战.分子靶向药物(molecular targeted agents),包括酪氨酸激酶抑制剂和单克隆抗体等,正是基于这些理论前提才得以出现和得到迅猛发展.他已逐渐成为PLC治疗的新宠,也代表了未来的发展方向.本文就新近出现的分子机制研究及靶向药物的特点及趋势作一综述.可以预见,分子机制研究的突破会创造更为有效的靶向药物,配合规范的综合治疗,最终可使PLC的治疗获得新成功.The treatment of primary liver cancer （PLC）is still challenging in China nowadays, and it fundamentally depends on the systematic knowledge of hepatocarcinogenesis. In recent years, the gradual clarification of the molecular pathogenesis of PLC has brought new opportunities and challenges to its treatment. Molecular targeted agents, including tyrosine kinase inhibitors and monoclonal antibodies, have appeared and developed rapidly since the mechanisms were elucidated. These agents have gradually became a preferred choice of treatment of PLC and represents the future trend. In this paper, we will review the molecular pathogenesis of PLC and the targeted agents.

关 键 词：分子生物学机制 分子靶向药物 原发性肝癌 

分 类 号：R735.7[医药卫生—肿瘤]